Kaempferol

• CAT Number: I003885
• CAS Number: 520-18-3
• Molecular Formula: C15H10O6
• Molecular Weight: 286.2
• Purity: ≥95%
• Target: Others
• Solubility: DMSO: ≥ 32 mg/mL
• Storage: 3 years -20C powder
• IC50: Kaempferol inhibits proliferation of ovarian cancer cells at 40μM or higher concentrations[2].
• InChIKey: IYRMWMYZSQPJKC-UHFFFAOYSA-N

Kaempferol(Kempferol) is a relatively common nontoxic, natural dietary compound which has been reported to reduce the risk of ovarian cancer.IC50 value: Kaempferol inhibits proliferation of ovarian cancer cells at 40μM or higher concentrations[2].Target: AnticancerKaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) is a relatively common nontoxic, natural dietary compound which has been reported to reduce the risk of ovarian cancer[1].in vitro: Kaempferol was found to inhibit estrogen receptor alpha expression in breast cancer cells and to induce apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Studies have shown that kaempferol also has anti-inflammatory effects via inhibition of interleukin-4 and cyclo-oxygenase 2 expression by suppressing Src kinase and downregulating the NFκB pathway. Kaempferol is also effective in inhibiting angiogenesis and inducing apoptosis in ovarian cancer cells [1]. kaempferol has a distinct epigenetic activity by inhibition of histone deacetylases (HDACs). In silico docking analysis revealed that it fits into the binding pocket of HDAC2, 4, 7 or 8 and thereby binds to the zinc ion of the catalytic center. Further in vitro profiling of all conserved human HDACs of class I, II and IV showed that kaempferol inhibited all tested HDACs [4].in vivo: Male BALB/c mice with ALI, induced by intranasal instillation of LPS, were treated or not with Kae (100 mg/kg, intragastrically) 1h prior to LPS exposure. Kae treatment attenuated pulmonary edema of mice with ALI after LPS challenge, as it markedly decreased the lung W/D ratio of lung samples, protein concentration and the amounts of inflammatory cells in BALF[3].Clinical trial:N/A

Reference

[1]. Haitao Luo, Bingbing Jiang, Bingyun Li, Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability. Int J Nanomedicine. 2012; 7: 3951-3959.
[2]. Haitao Luo, Gary O. Rankin, Zhaoliang Li, Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway. Food Chem. 2011 September 15; 128(2): 513-519.
[3]. Chen X, Yang X, Liu T, Kaempferol regulates MAPKs and NF-κB signaling pathways to attenuate LPS-induced acute lung injury in mice. Int Immunopharmacol. 2012 Oct;14(2):209-16.
[4]. Berger A, Venturelli S, Kallnischkies M, Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. J Nutr Biochem. 2012 Nov 14. pii: S0955-2863(12)00194-5.